Centrum für Operative Urologie Bremen

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

G. Mickisch, M. Gore, Bernard Escudier et al. · British Journal of Cancer · 2009 · 66 citations · Full text

Identification of multidrug resistance‐associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine

J.P. van Brussel, M.A. Oomen, Paula J.M. Vossebeld et al. · British Journal of Urology · 2004 · 31 citations

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

Bohuslav Melichar, Sergio Bracarda, B. Yа. Alekseev et al. · Annals of Oncology · 2013 · 31 citations

Urology, Genitourinary Cancer, Medicine +5

Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial

Paul C.M.S. Verhagen, Mark F. Wildhagen, A.M. Verkerk et al. · World Journal of Urology · 2013 · 25 citations

Urology, Genitourinary Cancer, Medicine +5

Multidisciplinary behavioural treatment of fecal incontinence and constipation after correction of anorectal malformation

Eberhard Schmiedeke, Monika Busch, Elektra Stamatopoulos et al. · World Journal of Pediatrics · 2008 · 21 citations

Fecal Incontinence, Urology, Anorectal Malformation +7